Tech Company Financing Transactions
Zymeworks Funding Round
On 1/8/2016, Zymeworks raised $61.5 million in Series A financing from BDC Venture Capital, Lumira Capital and Brace Pharma.
Transaction Overview
Company Name
Announced On
1/8/2016
Transaction Type
Venture Equity
Amount
$61,500,000
Round
Series A
Investors
BDC Venture Capital (Lead Investor) (Dion Madsen)
Lumira Capital (Lead Investor) (Daniel Hetu)
Proceeds Purpose
Proceeds of the financing will support clinical development of Zymeworks' lead therapeutic candidates, ZW25 and ZW33, which the Company plans to move into clinical development later this year.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1385 West 8th Ave. 540
Vancouver BC, V6H 3V9
Canada
Vancouver BC, V6H 3V9
Canada
Phone
Website
Email Address
Overview
Zymeworks (NYSE: ZYME) is committed to the development of best in class antibody and protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks combines proprietary molecular simulation technology with high performance computing to design and optimize protein therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ali Tehrani
Chief Financial Officer
Neil Klompas
Chief Technical Officer
Surjit Dixit
VP - General Counsel
Jennifer Kaufman-Shaw
VP - Human Resources
Wajida Leclerc
Browse more venture capital transactions:
Prev: 1/8/2016: ASLAN Pharmaceuticals venture capital transaction
Next: 1/8/2016: appsFreedom venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs